ARCUS BIOSCIENCES INC (RCUS) Stock Analyst Ratings
USA - New York Stock Exchange - NYSE:RCUS - US03969F1093 - Common Stock
23.18 USD
+1.13 (+5.12%)
22.81 USD
-0.37 (-1.6%)
ChartMill assigns a Buy % Consensus number of 82% to RCUS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 33.01. This target is 42.41% above the current price.
RCUS was analyzed by 19 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about RCUS.
In the previous month the buy percentage consensus was at a similar level.
RCUS was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-30 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-10-29 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-13 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-07 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-08-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-05-08 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-05-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-23 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-26 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-02-19 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-02-18 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-02-18 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-25 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-21 | HC Wainwright & Co. | Initiate | Neutral |
| 2024-10-08 | Wells Fargo | Initiate | Overweight |
| 2024-10-07 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-10-03 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-10-03 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-08-09 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-07-08 | Barclays | Maintains | Overweight -> Overweight |
| 2024-07-05 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-06-24 | Truist Securities | Maintains | Buy -> Buy |
| 2024-06-03 | Citigroup | Maintains | Buy -> Buy |
| 2024-05-09 | Wedbush | Reiterate | Outperform -> Outperform |
ARCUS BIOSCIENCES INC / RCUS FAQ
What is the average price target for ARCUS BIOSCIENCES INC (RCUS) stock?
19 analysts have analysed RCUS and the average price target is 33.01 USD. This implies a price increase of 42.41% is expected in the next year compared to the current price of 23.18.
What is the consensus rating for ARCUS BIOSCIENCES INC (RCUS) stock?
The consensus rating for ARCUS BIOSCIENCES INC (RCUS) is 82.1053 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover ARCUS BIOSCIENCES INC (RCUS) stock?
The number of analysts covering ARCUS BIOSCIENCES INC (RCUS) is 19.